Results

Total Results: 1,484 records

Showing results for "indicated".

121. Executive Summary: Radiation Therapy for Metastatic Bone Disease: Effectiveness and Harms (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-265-radiation-bone-disease-summary.pdf
     August 01, 2023 - Comparisons of EBRT versus strontium and versus bisphosphonates alone indicated no differences in pain

122. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/psoriasis-chronic_research-protocol.pdf
     January 10, 2012 - contraindicated in patients with psoriasis, therapeutic use of topical or intralesional injections may be indicated … complete (2009) Hydroxyurea‡ Hydrea ® (oral capsule) Bristol-Myers Squibb Company Indicated … Guidelines on clinical investigation of medicinal products indicated for the treatment of psoriasis

123. CER 244 Evidence Summary: Safety of Vaccines Used for Routine Immunization in the United States: An Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/cer-244-safety-vaccines-update-evidence-summary.pdf
     May 01, 2021 - CER 244 Evidence Summary: Safety of Vaccines Used for Routine Immunization in the United States: An Update Comparative Effectiveness Review Number 244 Safety of Vaccines Used for Routine Immunization in the United States: An Update Evidence Summary Main Points Background and Purpose Considere…

124. Kidney-Disease-Medicine Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/kidney-disease-medicine_executive.pdf
     January 01, 2012 - Kidney dysfunction is indicated by a glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m2 … However, potential CKD treatments may be indicated for conditions associated with CKD. … are significantly improved with a higher treatment dose or by treatment to a stricter target than indicated … address whether treatments improved outcomes in CKD subgroups in which treatments were not already indicated

125. Stem-Cell-Children Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/stem-cell-children_executive.pdf
     February 01, 2012 - 1 Comparative Effectiveness Review Number 48 Hematopoietic Stem-Cell Transplantation in the Pediatric Population Executive Summary Background Hematopoietic stem-cell transplantation (HSCT) refers to a procedure in which hematopoietic progenitor cells, including repopulating stem cells, are infused to restore …

126. Updating the Framework for AHRQ’s National Healthcare Quality and Disparities Report (NHQDR) (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/updating-framework-protocol.pdf
     September 06, 2023 - Updating the Framework for AHRQ’s National Healthcare Quality and Disparities Report (NHQDR) Evidence-based Practice Center Technical Brief Protocol Project Title: Updating the Framework for AHRQ’s National Healthcare Quality and Disparities Report (NHQDR) I. Background and Objectives for the Technical…

127. Comparative Effectiveness Review No. 234 Evidence Summary: Management of Primary Headaches in Pregnancy (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-234-headaches-pregnancy-summary.pdf
     November 01, 2020 - Comparative Effectiveness Review No. 234 Evidence Summary: Management of Primary Headaches in Pregnancy Comparative Effectiveness Review Number 234 Management of Primary Headaches in Pregnancy Evidence Summary Main Points • Prevention of primary headache in women who are pregnant (or attempting to become pre…

128. Executive summary_Comparative Effectiveness Review No. 276: Diagnosis and Management of Obsessive Compulsive Disorders in Children (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-276-ocd-executive-summary.pdf
     December 01, 2024 - Network meta-analyses indicated that remote ERP is equivalent to in-person ERP for OCD symptoms and

129. Disposition of Comments_Comparative Effectiveness Review No. 272_Genitourinary Syndrome of Menopause: A Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-272-genitourinary-syndrome-disposition-comments.pdf
     July 31, 2024 - • Several reviewers indicated a need to clarify eligibility criteria regarding non-U.S.

130. PULMONARY with "Discussions" in Exec Summary (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1312.pdf
     December 01, 2013 - We present summaries on three topics (indicated below by an asterisk) that emerged as having high-impact … Ivacaftor tablets are indicated for oral administration, one 150 mg dose every 12 hours for patients … also being evaluated in 10 other CFTR gene mutations known to cause CF, which could expand the indicated … ivacaftor’s price is considered to be the highest-cost drug therapy on the market today, the company indicated … One report indicated that hospitals in Europe pay about $60,000 for each machine.60 Clinical Pathway

131. Quantitative Synthesis II: Interactive Quiz (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/selecting-evidence-quiz.ppt
     May 29, 2025 - Quantitative Synthesis II: Interactive Quiz When To Select Observational Studies Interactive Quiz Prepared for: The Agency for Healthcare Research and Quality (AHRQ) Training Modules for Systematic Reviews Methods Guide www.ahrq.gov When To Select Observational Studies Interactive Quiz When should observational …

132. Quantitative Synthesis II: Interactive Quiz (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/selecting-evidence-quiz.ppt
     May 29, 2025 - Quantitative Synthesis II: Interactive Quiz When To Select Observational Studies Interactive Quiz Prepared for: The Agency for Healthcare Research and Quality (AHRQ) Training Modules for Systematic Reviews Methods Guide www.ahrq.gov When To Select Observational Studies Interactive Quiz When should observational …

133. Disposition of Comments Report for Otitis Media With Effusion (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/ear-infection_disposition-comments.pdf
     May 04, 2013 - We have indicated that we could not find studies focused on subgroups (page ES-20, Research Gaps): … We limited our discussion to tympanoscentesis, pneumatic otoscopy, and hearing loss; we also indicated … The strength of evidence table in the results section indicated that there were mixed findings for … We have indicated in the research gaps the methodological limitations of many studies. … We have further indicated that use of a common outcome protocol would facilitate pooling results.

134. Disposition of Comments Report for Comparative Effectiveness Review No. 131 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/crohns-disease_disposition-comments.pdf
     February 25, 2014 - Please note in the review that CZP is not indicated for the induction of remission of Crohn’s disease … We considered all drugs for induction and maintenance, regardless of how they are indicated. … For those treatments that are not indicated for Crohn’s disease, the recommended doses evaluated in … Infliximab does have the following FDA indications in pediatric patients: INFLIXIMAB is indicated for … As indicated above, we revised the summary of key findings and added a section offering a clinical

135. Insulin Delivery and Glucose Monitoring Methods: Future Research Needs (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/insulin-blood-sugar_research.pdf
     August 01, 2015 - As indicated in the analytic framework, we focused on the population of patients having type 1 or type … The stakeholders indicated that additional research was needed for children (age less than 13 years) … As indicated above, such trials should be accompanied by efforts to assess the ES-6 comparative … As indicated in the analytic framework, we focused on the population of patients having type 1 or type … As indicated above, such trials should be accompanied by efforts to assess the comparative effectiveness

136. S108 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s108.pdf
     October 01, 2007 - Values less than 1 indicated bias away from the null, values of 1 indicated an absence of bias, and values … greater than 1 indicated bias toward the null.42 In this simulation, confounding produced unadjusted

137. Ced -Appendix-2 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/ced%20-appendix-2.xlsx
     May 29, 2025 - Summary_Out of Scope Comments There were many comments that were outside of the scope of this project in that they addressed the CED process rather including when and how it should be implemented. Multiple comments proposed that AHRQ should undertake a similar exercise to this one, with the goal of revising the CED p…

138. Evidence Summary for Treatments for Acute Pain: A Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/cer-240-acute-pain-evidence-summary.pdf
     December 01, 2020 - Low back pain (38 trials): Evidence indicated that there might be no difference between an opioid versus

139. Disposition of Comments_Systematic Review_The Effect of Protein Intake on Health: A Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/effect-protein-intake-disposition-comments.pdf
     November 22, 2024 - Disposition of Comments_Systematic Review_The Effect of Protein Intake on Health: A Systematic Review Systematic Review Disposition of Comments Report Title: The Effect of Protein Intake on Health: A Systematic Review Draft report available for public comment from May 1, 2024, to May 31, 2024. Citation: Lamina …

140. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/vte-prophyalaxis_research-protocol.pdf
     March 01, 2011 - medical patients Dalteparin sodium (Fragmin ® ) Subcutaneous 5,000 IU QD Eisai/Pfizer 1994 Indicated … sodium (Innohep ® ) Subcutaneous 3,500 IU QD to 4500 IU SC daily LEO Pharma/Celgene 2000 Indicated … Xa Inhibitors Fondaparinux (Arixtra ® ) Subcutaneous 2.5 mg QD GSK 2001 Indicated … , 2012 prophylaxis Rivaroxaban (Xarelto ® ) Oral 10 mg QD Johnson and Johnson 2011 Indicated